Survival implications of prescription opioid and benzodiazepine use in lung transplant recipients: Analysis of linked transplant registry and pharmacy fill records.

Survival implications of prescription opioid and benzodiazepine use in lung transplant recipients: Analysis of linked transplant registry and pharmacy fill records.
复制标题

DOI:
10.1016/j.healun.2021.02.004
复制
发表时间:
2021-06
期刊:
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
影响因子:
--
通讯作者:
Schnitzler MA
Schnitzler MA
中科院分区:
其他
文献类型:
--
作者:
Lentine KL;Salvalaggio PR;Caliskan Y;Lam NN;McAdams-DeMarco M;Axelrod D;Segev DL;Myaskovsky L;Dew MA;Bruschwein H;Levine DJ;Sweet S;Hess GP;Kasiske BL;Schnitzler MA

文献摘要

参考文献

被引文献

相似文献

Prescription opioid and benzodiazepine use have been associated with morbidity and mortality among some groups of solid organ transplant recipients, but implications for outcomes among lung transplant patients are not well described. We conducted a retrospective cohort study using linked national transplant registry and pharmaceutical records to characterize the associations between benzodiazepine and opioid prescription fills in the years before and after lung transplant (2006–2017), with risk-adjusted posttransplant survival (adjusted hazard ratio, LCLaHRUCL). Among 11,568 recipients, 33.7% filled an opioid prescription, and 25.8% filled a benzodiazepine prescription before transplant. Compared to patients without prescriptions, those who filled both short- and long-acting benzodiazepine prescriptions before transplant had 2-fold higher mortality in the first year posttransplant (aHR, 1.392.123.21), after adjustment for baseline factors and opioid fills, while pretransplant opioid fills were not associated with posttransplant mortality after adjustment for benzodiazepine fills. Pretransplant opioid and benzodiazepine use strongly predicted more use after transplant. Fills of both short- and long-acting benzodiazepines in the first year posttransplant were associated with 77% increased mortality >1-to-2 years posttransplant (aHR, 1.061.772.96). Compared with no posttransplant opioid fills, there was a dose-dependent association between opioid fills and adjusted mortality risk (level 2: aHR, 1.171.501.92 to level 4: aHR, 1.562.012.59). These effects were independent, and interactions were not detected. Benzodiazepine prescription fills before and after lung transplant, and opioid fills after transplant, are independently associated with posttransplant mortality. Review of benzodiazepine and opioid use history is relevant to risk-stratifying patients before and after lung transplant.
DOI: 10.1016/j.pain.2004.09.019
发表时间: 2004-12-01
期刊: PAIN
影响因子: 7.4
作者:
Kalso, E;Edwards, JE;McQuay, HJ
通讯作者: McQuay, HJ
DOI: 10.1177/0269216314566839
发表时间: 2015-05-01
影响因子: 4.4
作者:
Colman, Rebecca;Singer, Lianne G.;Downar, James
通讯作者: Downar, James
DOI: 10.1097/tp.0000000000003050
发表时间: 2020-08-01
期刊: TRANSPLANTATION
影响因子: 6.2
作者:
Vahidy, Sana;Li, David;Halloran, Kieran
通讯作者: Halloran, Kieran
DOI: 10.1080/10826084.2016.1276189
发表时间: 2017-08-24
影响因子: 2
作者:
Campbell CI;Kline-Simon AH;Von Korff M;Saunders KW;Weisner C
通讯作者: Weisner C
DOI: 10.1136/bmj.j760
发表时间: 2017-03-14
期刊: BMJ (Clinical research ed.)
影响因子: --
作者:
Sun EC;Dixit A;Humphreys K;Darnall BD;Baker LC;Mackey S
通讯作者: Mackey S